ARTICLE | Clinical News
FDA approves second generic of thrice-weekly Copaxone
February 16, 2018 8:47 PM UTC
The Sandoz Ltd. unit of Novartis AG (NYSE:NVS; SIX:NOVN) and partner Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said FDA approved an ANDA for thrice-weekly 40 mg/mL Glatopa glatiramer acetate injection as a generic version of multiple sclerosis drug Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA).
Novartis and Momenta confirmed Sandoz has launched 40 mg/mL Glatopa, but Novartis spokesperson Eric Althoff declined to disclose its wholesale acquisition cost (WAC)...
BCIQ Company Profiles
BCIQ Target Profiles